Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab.

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab.

J Clin Endocrinol Metab. 2016 Aug 29;:jc20162300

Authors: de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B

Abstract
CONTEXT: Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 receptor (PD-1) monoclonal antibody (mAb), remains to be fully characterized.
OBJECTIVE: To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction.
DESIGN AND SETTING: Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access program at a referral oncology center. (18)Fluorodeoxyglucose uptake on positron emission tomography/computed tomography ((18)FDG-PET/CT) was reviewed in cases compatible with inflammatory thyroiditis.
PATIENTS: 99 patients with advanced melanoma (aged 26.3-93.6 years; 63.6% females) who received at least 1 administration of pembrolizumab.
MAIN OUTCOME MEASURES: Patient characteristics, thyroid function (TSH, fT4), thyroid autoantibodies and (18)FDG-PET/CT.
RESULTS: 18 adverse events of thyroid dysfunction were observed in 17 patients. Thyrotoxicosis occurred in 12 patients of which 9 evolved to hypothyroidism. Isolated hypothyroidism was present in 6 patients. Levothyroxine therapy was required in 10 of 15 hypothyroid patients. Thyroid autoantibodies were elevated during thyroid dysfunction in 4 of 10 cases. Diffuse increased (18)FDG uptake by the thyroid gland was observed in all 7 thyrotoxic patients who progressed to hypothyroidism.
CONCLUSIONS: Thyroid dysfunction is common in melanoma patients treated with pembrolizumab. Hypothyroidism and thyrotoxicosis related to inflammatory thyroiditis are the most frequent presentations. Serial measurements of thyroid function tests are indicated during anti-PD-1 mAb therapy. Thyrotoxicosis compatible with inflammatory thyroiditis was associated with diffuse increased (18)FDG uptake by the thyroid gland. The prospective role of thyroid autoantibodies should be further investigated together with the histopathological correlates.

PMID: 27571185 [PubMed - as supplied by publisher]

from Head and Neck on PubMed via xlomafota13 on Inoreader http://ift.tt/2c7sfbL


http://ift.tt/2c597KS